<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Neurosci</journal-id>
<journal-id journal-id-type="hwp">jneuro</journal-id>
<journal-id journal-id-type="pmc">jneurosci</journal-id>
<journal-id journal-id-type="publisher-id">J. Neurosci</journal-id>
<journal-title-group>
<journal-title>The Journal of Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">0270-6474</issn>
<issn pub-type="epub">1529-2401</issn>
<publisher>
<publisher-name>Society for Neuroscience</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31578233</article-id>
<article-id pub-id-type="pmc">6855690</article-id>
<article-id pub-id-type="publisher-id">1261-19</article-id>
<article-id pub-id-type="doi">10.1523/JNEUROSCI.1261-19.2019</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Articles</subject>
<subj-group>
<subject>Cellular/Molecular</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling a Neurexin-3α Human Mutation in Mouse Neurons Identifies a Novel Role in the Regulation of Transsynaptic Signaling and Neurotransmitter Release at Excitatory Synapses</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-4466-5920</contrib-id>
<name>
<surname>Restrepo</surname>
<given-names>Susana</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Langer</surname>
<given-names>Nora J.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nelson</surname>
<given-names>Kylan A.</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-0568-634X</contrib-id>
<name>
<surname>Aoto</surname>
<given-names>Jason</given-names>
</name>
<xref ref-type="aff" rid="aff1"></xref>
</contrib>
<aff id="aff1">Department of Pharmacology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence should be addressed to Jason Aoto at <email>jason.aoto@ucdenver.edu</email></corresp>
<fn fn-type="con">
<p>Author contributions: S.R. and J.A. designed research; S.R., N.J.L., K.A.N., and J.A. performed research; S.R. and J.A. contributed unpublished reagents/analytic tools; S.R., N.J.L., K.A.N., and J.A. analyzed data; S.R., N.J.L., and J.A. wrote the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>13</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>5</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 6 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>39</volume>
<issue>46</issue>
<fpage>9065</fpage>
<lpage>9082</lpage>
<history>
<date date-type="received">
<day>30</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>13</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 the authors</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="zns04619009065.pdf"></self-uri>
<abstract>
<p>Presynaptic α-neurexins are highly expressed and more frequently linked to neuropsychiatric and neurodevelopmental disorders than β-neurexins. However, how extracellular sequences specific to α-neurexins enable synaptic transmission is poorly understood. We identified a mutation in an extracellular region of neurexin-3α (A687T), located in a region conserved among α-neurexins and throughout vertebrate evolution, in a patient diagnosed with profound intellectual disability and epilepsy. We systematically interrogated this mutation using a knockdown-replacement approach, and discovered that the A687T mutation enhanced presynaptic morphology and increased two critical presynaptic parameters: (1) presynaptic release probability, and (2) the size of the readily releasable pool exclusively at excitatory synapses in mixed sex primary mouse hippocampal cultures. Introduction of the mutation <italic>in vivo</italic> and subsequent analysis in <italic>ex vivo</italic> brain slices made from male and female mice revealed a significant increase in excitatory presynaptic neurotransmission that occluded presynaptic but not postsynaptic LTP. Mechanistically, neurexin-3α<sup>A687T</sup> enhanced binding to LRRTM2 without altering binding to postsynaptic neuroligin-1. Thus, neurexin-3α<sup>A687T</sup> unexpectedly produced the first neurexin presynaptic gain-of-function phenotype and revealed unanticipated novel insights into how α-neurexin extracellular sequences govern both transsynaptic adhesion and presynaptic neurotransmitter release.</p>
<p><bold>SIGNIFICANCE STATEMENT</bold> Despite decades of scientific scrutiny, how precise α-neurexin extracellular sequences control synapse function remains enigmatic. One largely unpursued avenue to identify the role of precise extracellular sequences is the interrogation of naturally occurring missense mutations. Here, we identified a neurexin-3α missense mutation in a compound heterozygous patient diagnosed with profound intellectual disability and epilepsy and systematically interrogated this mutation. Using <italic>in vitro</italic> and <italic>in vivo</italic> molecular replacement, electrophysiology, electron microscopy, and structure–function analyses, we reveal a novel role for neurexin-3α, unanticipated based on α-neurexin knock-out models, in controlling presynaptic morphology and neurotransmitter release at excitatory synapses. Our findings represent the first neurexin gain-of-function phenotype and provide new fundamentally important insight into the synaptic biology of α-neurexins.</p>
</abstract>
<kwd-group>
<kwd>α neurexin</kwd>
<kwd>human mutation</kwd>
<kwd>neurexin</kwd>
<kwd>presynaptic release</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>twij</meta-name>
<meta-value>true</meta-value>
</custom-meta>
<custom-meta>
<meta-name>special-property</meta-name>
<meta-value>cellular</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>